Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Multi-centre study to compare the the safety, tolerability, and immunogenicity of the refrigerator-stable formulation of the Varicella vaccine to that of the frozen formulation in Healthy children

Trial Profile

Randomised, Double-blind, Multi-centre study to compare the the safety, tolerability, and immunogenicity of the refrigerator-stable formulation of the Varicella vaccine to that of the frozen formulation in Healthy children

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

At a glance

  • Drugs Varicella zoster virus vaccine live (Primary) ; Measles mumps and rubella virus vaccine
  • Indications Varicella zoster virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 04 Sep 2018 New trial record
    • 23 Aug 2018 Primary endpoint (Immune Response) has been met, according to the results published in the Vaccine.
    • 23 Aug 2018 Results published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top